Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update

April 1, 2019 7:30 AM

- Recent transformative agreement to acquire innovative XCART platform technology positions Company to drive significant momentum - XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually FRAMINGHAM, MA / ACCESSWIRE / April 1, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"),...

Read more

Human milk oligosaccharides for health

March 28, 2019 5:40 AM

RHEINBREITBACH / ACCESSWIRE / March 28, 2019 / Human mothers are unique because they produce breast milk which is very different from other species on our planet. Human milk has a very high concentration of special sugars known as human milk oligosaccharides (HMOs). These HMOs are the third most abundant solid component of human milk after lactose and fat. More than 200 structurally different HMOs have been identified. The most abundant HMO is...

Read more

Dyadic Reports 2018 Year End Results and Recent Developments

March 27, 2019 4:30 PM

Market capitalization more than doubled since January 2018Company becomes a full reporting entity subject to the reporting requirements of Section 13(a) of the Securities and Exchange Act of 1934Company has applied to have its common stock listed on the NASDAQ Capital Markets Exchange ("NASDAQ")Nine funded proof of concept research collaborations signed in 2018 and two new collaborations in 2019Improved scientific data generated, reflecting...

Read more

Pressure BioSciences Names the Vogel Laboratory at New York University's Center for Genomics and Systems Biology a Center of Excellence

March 27, 2019 8:20 AM

Collaboration with Dr. Christine Vogel and Colleagues in NYU's Internationally Recognized "Hub of Science" Center Will Provide Scientists Immediate Access to PBI's Innovative and Proprietary Pressure-Based Platform Technologies SOUTH EASTON, MA / ACCESSWIRE / March 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and...

Read more

Calmare Therapeutics Receives Two Favorable Rulings In Delaware Chancery Court

March 25, 2019 11:37 AM

FAIRFIELD, CT / ACCESSWIRE / March 25, 2019 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC), the pain mitigation company ("Calmare" or the "Company"), announced today that, on March 15, 2019, Calmare won two significant rulings from the Delaware Court of Chancery brought against it and certain of its directors by Stanley Yarbro, another director. The Delaware Court rejected Yarbro's motion for a summary judgment to declare that he had been...

Read more

Dyadic to Present at Three Upcoming Investor Conferences

March 25, 2019 8:50 AM

JUPITER, FL / ACCESSWIRE / March 25, 2019 / Dyadic International, Inc. (the "Company") (OTCQX: DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb and Chief Accounting Officer, Ping Rawson will be presenting at the following three upcoming investor conferences:Sidoti & Company Spring Conference - Presenter - Mark EmalfarbNew York City, NYThursday, March 28, 2019 12:55 p.m. ETMicroCap Spring Summit -...

Read more

Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations

March 22, 2019 2:40 PM

GOLDEN, CO / ACCESSWIRE / March 22, 2019 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2019 financial results of operations. Vitro Diagnostics Inc. (''Vitro Biopharma'') is pleased to announce a record 1st quarter in Stem Cell Revenues. Vitro Biopharma recorded 1st quarter revenues of $192,895 vs $87,185, an increase of 121% over the same comparative quarter last year. In addition,...

Read more

American CryoStem Completes Cooperative Framework Agreement to Expand Market Presence in Japan

March 20, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 20, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has completed a Cooperative Framework Agreement with Shonan Beauty Clinic, and MEDINET Co., Ltd. which will provide CRYO with greater access to...

Read more

Calmare Therapeutics Has $10.4 Million Judgment Vacated by The U.S. Court of Appeals for The Second Circuit

March 19, 2019 11:28 AM

FAIRFIELD, CT / ACCESSWIRE / March 19, 2019 / Calmare Therapeutics Incorporated, (OTC PINK: CTTC) (''CTI''), the pain mitigation company (''Calmare''), had a $10.4 million judgment vacated by the United States Court of Appeals for the Second Circuit (the ''Second Circuit''). On September 29, 2017, the U.S. District Court for the District of Connecticut (the ''District Court'') entered a final judgment awarding GEOMC Co., Ltd. - a South Korea...

Read more

Molecular Partners Publishes Audited Financial Results for 2018 and Annual Report 2018

March 15, 2019 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2019 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today published its audited Financial Results for 2018 and the company's 2018 Annual Report. The Audited Financial Results for 2018 and the company's 2018 Annual Report are available on the investors section of the company' website. Financial...

Read more

BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations

March 14, 2019 4:05 PM

BELBUCA® prescription growth further accelerated to an all-time high during the fourth quarter Company increases Belbuca 2019 net sales expectations to $80-$85 million Operating cash flow to become positive in 2019 Long-term potential for BELBUCA net sales believed to be $250 - $300 million Conference Call and Webcast scheduled for 4:30 pm ET today RALEIGH, NC / ACCESSWIRE / March 14, 2019 / BioDelivery Sciences International, Inc....

Read more

Glauconix Biosciences Completes Pilot Study Using Nemus Biosciences' Bioengineered Cannabinoid-Based Compound for Glaucoma Treatment

March 14, 2019 4:55 AM

Studyconfirms intraocular pressure-lowering effects of cannabinoid-based therapeutic, proving promising novel treatment for glaucoma ALBANY, NY / ACCESSWIRE / March 14, 2019 / Glauconix Biosciences Inc., a specialty pharmaceutical company that uses its patented platform technology to develop human 3D ocular tissues that mimic the fluid dynamics in the eye to expedite and de-risk the R&D of ophthalmic treatments while reducing development...

Read more

Dyadic to Report Year End 2018 Financial Results on Wednesday March 27, 2019

March 13, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / March 13, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2018 after the...

Read more

Vitro Biopharma Receives Approval for a Stem Cell Clinical Trial for Musculoskeletal Conditions by the Bahamas Ministry of Health

March 12, 2019 9:30 AM

GOLDEN, CO / ACCESSWIRE / March 12, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma announced receipt of provisional approval from the National Stem Cell Ethics Committee (NSCEC) of the Ministry of Health of the Commonwealth of the Bahamas for a clinical trial entitled ''Vitro Biopharma Allogeneic Mesenchymal Stem Cell Therapy for Musculoskeletal Conditions''. This broadens Vitro Biopharma's expansion into highly regulated...

Read more

Dyadic International to Present at the 2019 LD Micro Virtual Conference

March 11, 2019 9:05 AM

LOS ANGELES, CA / ACCESSWIRE / March 11, 2019 / Dyadic International (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flexible commercial scales, today announced that it will be presenting at the second annual LD Micro Virtual Conference on Wednesday, March 13, 2019 at 12:40 PM EST....

Read more

Molecular Partners to Present at the Cowen And Company 39th Annual Healthcare Conference

March 11, 2019 2:00 AM

Company to highlight the progress on its clinical DARPin®compounds, discuss MP0310 in its strategic partnership with Amgen and update on the initiation of a research project to explore DARPin®molecules targeting peptide MHC complexes supported by Gilead ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 11, 2019 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to...

Read more

CTD Holdings to Present at Webinar for Patients and Families on Initial Clinical Trial Data

March 8, 2019 8:00 AM

Webinar Hosted by US Non-Profit Organization Supporting Patients with Niemann-Pick Disease ALACHUA, FL / ACCESSWIRE / March 8, 2019 / CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced its participation in a webinar organized by the National Niemann-Pick Disease Foundation (NNPDF), the U.S. national advocacy...

Read more

Sangui BioTech International Inc.: Patent granted to Sangui for possible Septic Shock treatment

March 6, 2019 4:30 AM

WITTEN / ACCESSWIRE / March 06, 2019 / The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmonary System**), Giessen, Germany. The studies conducted by the ECCPS have resulted in proof-of concept data, utilizing a related technology to Sangui's unique...

Read more

Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

March 5, 2019 9:27 AM

FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs, today announced it has entered into a securities purchase agreement with...

Read more

Pressure BioSciences and The Steinbeis Centre Combine Efforts to Develop Revolutionary Method Based on Optimizing Disease-Fighting Antibodies

March 4, 2019 8:04 AM

Increasing the Understanding of Disease Proteins Recognized by Antibodies Should Accelerate Development of Optimized Drugs, Vaccines, and Diagnostics Across Diseases and Conditions from Cancers to Crohn's and Transplant Rejections to Neurodegenerative Diseases SOUTH EASTON, MA / ACCESSWIRE / March 4, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of...

Read more